期刊文献+

HCCR mRNA在原发性肝细胞癌患者中的表达及临床意义 被引量:2

Relationship between HCCR m RNA and primary hepatocellular carcinoma
下载PDF
导出
摘要 目的探讨人宫颈癌基因(human cervical cancer oncogene,HCCR)m RNA在原发性肝细胞癌(primary hepatocellular carcinoma,PHC)患者中的表达及其临床意义。方法采用RT-PCR检测PHC癌组织、癌旁肝组织和肝硬化组织及各组外周血单个核细胞(peripheral blood mononuclear cell,PBMC)中的HCCR m RNA表达水平,并进行分析。结果 HCCR m RNA在PHC组织中的相对表达强度为0.83±0.10,癌旁肝组织中的相对表达强度为0.12±0.07,肝硬化组织中的相对表达强度为0.57±0.12,三组均数间两两比较,差异均有统计学意义(P<0.05)。PBMC中,肝癌患者HCCR m RNA的表达强度为0.55±0.06,肝硬化患者HCCR m RNA的表达强度为0.34±0.04,而正常人未检测出,差异均有统计学意义(P<0.05)。结论 PHC和肝硬化患者的组织和PBMC中HCCR表达明显增高,HCCR基因可能参与了PHC的发生与发展,其与PHC的恶变演进有一定的相关性。 Objective To detect the expression level of HCCR mRNA in primary hepatocellular carcinoma(PHC) and explore its clinical significance. Methods Reverse transcription polymerase chain reaction was used to detect the expression of HCCR mRNA in PHC tissues, surrounding non-tumor tissues, hepatocirrhosis tissues and peripheral blood mononuclear cells. Results The relative expression level of HCCR mRNA in PHC tissues was 0.83±0.10, and which in surrounding non-tumor tissues and the hepatocirrhosis tissues were 0.12±0.07 and 0.57±0.12, respectively. The differences in the three groups had statistical significance (P〈0.05). The relative mRNA level of HCCR in the PBMC of PHC patients were 0.55 ±0.06 and which in the hepatocirrhosis pa-tients were 0.34±0.04, while HCCR expression in the normal ones could not detected. The differences had statistical significance (P〈0.05). Conclusion The mRNA levels of HCCR in PHC tissues, hepatocirrhosis tissues and their PBMC are up-regulated sig-nificantly, which suggests that HCCR maybe involved in the occurrence and development of PHC, and maybe related to the ma-lignant change of PHC.
出处 《实验与检验医学》 CAS 2014年第6期654-657,共4页 Experimental and Laboratory Medicine
基金 湖南省自然科学基金项目(NO.12JJ3089)
关键词 人宫颈癌基因 原发性肝细胞癌 肝硬化 mRNA Human cervical cancer oncogene Primary hepatocellular carcinoma Hepatocirrhosis mRNA
  • 相关文献

参考文献5

二级参考文献192

  • 1杜长征,李惠平,马力文,付卫,王墨培,贾廷珍,赵红梅,侯宽永.中国乳腺癌患者p53表达临床生物学意义的Meta分析[J].中国癌症杂志,2005,15(6):514-517. 被引量:23
  • 2Lvkovic-Kapicl T,Knezevic-Usaj S,Panjkovic M,et al.The influence of aging on pathologic and immunobiologic parameters of invasive ductal breast carcinoma.[J].Vojnosanit Pregl,2006,63(11):921-927.
  • 3Soussi T,Beroud C.Assessing TP53 status in human tumors to evaluate clinical outcome[J].Nat Rev Cancer,2001,1(3):233-240.
  • 4Petitjean A,Mathe E,Kato S,et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:Lessons from recent developments in the IARC TP53 database[J].Hum Mutant,2007,28(6):622-629.
  • 5Do TN,Rosal RV,Drew L,et al.Preferential induction of necrosis in human breast cancer cell by a p53 peptide derived from the MDM2 binding site[J].Oncogcne,2003,22(10):1431-1444.
  • 6Wojcik I,Szybka M,Golanska E,et al.Abnormalities of the P53,MDM2,BCL2 and BAX genes in acute leukemla's[J].Neoplasm,2005,52(4):318-324.
  • 7Vousden KH,Lane DP.p53 in health and disease[J].Nat Rev Mol Cell Bicol,2007,8:275-283.
  • 8Bartek J,Iggo R,Gaannon J,et al.Genetic and immunochemical analysis of mutant p53 in human breast cancer cell line[J].Oncogene,1990,5(6):893-899.
  • 9Norberg T,Klaar S,Karf G,et al.Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort[J].Cancer Res,2001,61(22):8317-8321.
  • 10Bensaad K,Tsuruta A,Selak MA,et al.A p53-inducible regulator of glycolsis and apoptosis[J].Cell,2006,126(1):107-120.

共引文献39

同被引文献25

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部